Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Chemotherapy in Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cT1b-T4b (cT4b - invasion in diaphragm, parenchyma of liver, spleen, pancreas, abdominal wall, small bowel, colon, distal part of splenic artery)~* cN0-3~* M0~* Age: 18 - 80~* ECOG: 0 - 1~* Histological type: adenocarcinoma~* Differentiation grade: G0 - G4~* No previous surgery~* No previous chemotherapy~* No concomitant severe comorbidity~* Written informed consent~Exclusion Criteria:~* cT1a, cT4b (invasion in truncus, hepatic artery, proximal part of splenic artery)~* Presense of distant metastases~* ECOG: 2 - 5~* Age: \<18 and \>80~* Severe concomitant comorbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Perioperative XELOX chemotherapy (Type: ACTIVE_COMPARATOR): Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP
- Perioperative FLOT chemotherapy (Type: EXPERIMENTAL): Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP

Based on this trial design, predict the completion outcome and termination type (if applicable).